Compare Recursion Pharmaceuticals Inc (RXRX) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B), while Vanguard Dividend Appreciation Index Fund ETF trades at $239.05 (market cap $132.40B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is far larger — about 61.9× Recursion Pharmaceuticals Inc's market cap, and Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and Vanguard Dividend Appreciation Index Fund ETF for 134 Days on average.
| RXRX | VIG | |
|---|---|---|
Market Cap | $2.14B | $132.40B |
Volume | 30,789,535 | 1,287,188 |
Sector | Health | — |
52-Week High | $6.79 | $246.61 |
52-Week Low | $2.84 | $210.70 |
Typical Hold Time | 23 Days | 134 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
VIG trades at $237.39, up 0.17% with a bullish technical signal from moving averages. The ETF focuses on dividend growth stocks with 10+ years of consecutive dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent quarterly dividend increased 7.5% year-to-date, though growth remains below historical averages. Technical indicators show support at $235-236 and resistance at $238-240.
Outlook remains positive for long-term investors seeking dividend growth, though the strategy sacrifices current yield for quality. Risks include slower dividend growth rates and exclusion of high-yield stocks by design. The ETF's quality focus provides defensive characteristics but may underperform during high-yield market environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
